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Low Fasting Plasma Glucose Level as a Predictor of
Cardiovascular Disease and All-Cause Mortality
Ming Wei, MD; Larry W. Gibbons, MD; Tedd L. Mitchell, MD; James B. Kampert, PhD;
Michael P. Stern, MD; Steven N. Blair, PED
Background—Although medical textbooks usually classify fasting plasma glucose,70 or 80 mg/dL (,3.89 or
4.44 mmol/L) as abnormal, the prognosis for patients with low fasting plasma glucose is unclear.
Methods and Results—We conducted prospective cohort studies among 40 069 men and women to investigate the
association between fasting plasma glucose levels and cardiovascular disease and all-cause mortality. We documented
a U-shaped relation between fasting plasma glucose and mortality. In addition to diabetes and impaired fasting glucose
levels, low fasting plasma glucose levels were also associated with high mortality. After multivariate adjustment for age,
sex, study population, ethnicity, current smoking status, high blood pressure, total cholesterol, body mass index,
triglycerides, history of cardiovascular disease and cancer, and a family history of cardiovascular disease, patients with
fasting plasma glucose,70 mg/dL (,3.89 mmol/L) had a 3.3-fold increased risk of cardiovascular disease mortality,
and patients with fasting plasma glucose 70 to 79 mg/dL (3.89 to 4.43 mmol/L) had a 2.4-fold increased risk compared
with the risk in patients with fasting plasma glucose 80 to 109 mg/dL (4.44 to 6.05 mmol/L) (tests for trendP,0.0001).
Participants with low fasting plasma glucose levels also had increased risk of all-cause mortality (test for trend
P,0.0001).
Conclusions—Participants with low fasting plasma glucose levels had a high risk of cardiovascular disease and all-cause
mortality. (Circulation. 2000;101:2047-2052.)
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Under normal physiological conditions, plasma glucoseconcentration is maintained within narrow limits by a
tightly regulated balance between glucose efflux from and
influx into the circulation.1 A normal plasma glucose level is
important for human energy and nutrition. It is known that
high fasting plasma glucose (FPG) levels and diabetes are
associated with a high incidence of cardiovascular disease
(CVD) and all-cause mortality.2–5 On the other hand, low
plasma glucose levels may cause brain and heart problems.1,6
Early studies of low FPG focused on brain damage during
hypoglycemia.6–8 Although medical textbooks usually clas-
sify FPG ,70 or 80 mg/dL (,3.89 or 4.44 mmol/L) as
abnormal,9,10 symptoms usually appear only when FPG is
,50 mg/dL (,2.78 mmol/L).11 There is a paucity of infor-
mation about the association between low plasma glucose
levels and cause-specific and all-cause mortality. In the
present study, we address this issue in 2 prospective studies
with a total follow-up of 350 552 person-years.
Methods
Subjects
Subjects for this study were 40 069 men and women 20 to 82 years
of age at baseline (mean, 43 years) from either the Aerobics Center
Longitudinal Study (ACLS) or the San Antonio Heart Study
(SAHS). The participants from the ACLS completed$1 preventive
medical evaluation at the Cooper Clinic in Dallas, Tex, between
1970 and 1989. Details of the study design and population charac-
teristics of this study are available in previous reports.12,13 Briefly,
this is a population-based prospective study. More than 97% of the
35 140 patients are white, 78% are men, and most had white-collar
or professional occupations. The baseline evaluation was performed
after participants gave their informed written consent for the initial
medical examination and subsequent registration in the follow-up
study. Examinations followed an overnight fast of$12 hours and
included personal and family health histories and a questionnaire on
demographic characteristics and health habits. All procedures were
administered by technicians who followed a standard manual of
operations.12 The study was reviewed and approved annually by the
Institutional Review Board at the Cooper Institute for
Aerobics Research.
The participants in the SAHS were randomly recruited between
1979 and 1988 from 3 types of neighborhoods: low-income barrios,
middle-income transitional neighborhoods, and high-income sub-
urbs. All men and nonpregnant women between 25 and 64 years of
age residing in the selected households were considered eligible for
the study. Of 4929 subjects, 62% were Mexican Americans, and 57%
were women. The baseline evaluation was performed after partici-
pants gave their informed written consent for the medical examina-
tion. Examinations followed an overnight fast of$12 hours and
included a questionnaire on demographic characteristics and health
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habits. Technicians who followed a standard manual of operations
administered all procedures. The study was approved by the Univer-
sity of Texas Health Science Center Institutional Review Board, and
all participants gave informed consent. Details of the study design
and sampling, recruitment, and field procedures of the SAHS have
been reported previously.4,14
We defined diabetes in this study according to the 1997 plasma
glucose criteria of the American Diabetes Association15: (1) For
impaired fasting glucose, FPG$110 mg/dL ($6.11 mmol/L) but
,126 mg/dL (,7.0 mmol/L); and (2) for diabetes, FPG$126
mg/dL (7.0 mmol/L). Subjects who did not meet this criterion but
who gave a history of diabetes and reported current therapy with
either oral antidiabetic agents or insulin also were considered to have
diabetes. In the SAHS, participants with a 2-hour postload glucose
level $200 mg/dL (11.1 mmol/L) also were considered to have
diabetes. The ACLS material did not include 2-hour postload glucose
data.
Primary outcome measures were CVD and all-cause mortality.
The National Death Index was used to identify possible decedents in
the ACLS. The National Death Index is an effective, accurate means
of ascertaining deaths in the general population with a sensitivity of
'96% and a specificity of 100%.16 Deaths were identified and
confirmed by follow-up interviews with next-of-kin in the SAHS,
and vital status was ascertained for 98% of the cohort.4 Death
certificates were obtained in both studies and coded by nosologists
according to the International Classification of Diseases, 9th Edition,
Revised. CVD mortality was defined as codes 390 to 459 and cancer
mortality as codes 140 to 208. Only the underlying cause of death
was used.
The 2 populations were pooled for analysis to increase statistical
power. Data were analyzed with the SAS statistical package.17
Interaction terms between population, ethnicity, sex, and other
independent variables were entered into the initial models to evaluate
possible interactions; however, no significant interactions were
found, and the primary analyses were on the pooled data. The
adjusted mortality rates were calculated by the direct method. We
used survival curves to estimate survival function against time and
Log [2log (survival time)] to check proportional hazards model
assumption. We used Cox proportional hazards models to estimate
the association between mortality and predictor variables after
adjustment for potential confounders.17,18 All probability values
provided are for 2-sided tests, and values ofP,0.05 were considered
statistically significant.
Results
Baseline characteristics adjusted for age, sex, ethnicity, and
study population are presented in Table 1. Body mass index,
total cholesterol, triglyceride, systolic blood pressure, diastol-
ic blood pressure, exercise tolerance, fasting insulin, and
2-hour postload insulin values were lower in individuals with
low FPG than in individuals with normal FPG. The preva-
lence of parental CVD and current smoking were higher in
participants with low FPG; however, the differences for these
variables were small, except for insulin level.
During an average follow-up of 8 years, there were 954
deaths, including 413 from CVD and 277 from cancer. We
first stratified data by every 10 mg/dL (0.555 mmol/L) for
mortality analysis. We found increased mortality in partici-
pants with diabetes and with FPG,80 mg/dL (,4.44
mmol/L). There were 1581 participants with diabetes, 4550
with impaired fasting glucose, and 1795 with FPG,80
mg/dL (,4.44 mmol/L). Among participants with low FPG,
11 had FPG,50 mg/dL (,2.78 mmol/L), 221 had FPG 50 to
69 mg/dL (2.78 to 3.88 mmol/L), and 1563 had FPG 70 to 79
mg/dL (3.89 to 4.43 mmol/L). Figure 1 shows the mortality
rates per 1000 person-years according to FPG levels. Subjects
in the SAHS, which included many Mexican Americans, had
a high prevalence of diabetes (8%) compared with subjects in
the ACLS (3%). The prevalence of low FPG was also higher
in Mexican Americans. There was a clear relation between
low FPG and mortality after adjustment for age, sex, and
study population. After exclusion or adjustment for history of
chronic disease, the magnitude of association between low
FPG and mortality did not change.
We then focused on the comparison between low FPG and
normal FPG. We first performed subgroup analyses in
women versus men, individuals aged$50 years versus those
aged,50 years, Mexican Americans versus non-Hispanic
whites, deaths in the first 4 years versus deaths later than 4
years, and SAHS versus ACLS separately. All associations
between low FPG and mortality were directionally similar in
these subgroup analyses. Compared with participants without
low FPG, those with low FPG had a substantially higher risk
of CVD and all-cause mortality in each subgroup analysis.
TABLE 1. Adjusted Baseline Characteristics of 33 658










Subjects, n 1795 31 863 z z z
Body mass index, kg/m2 24.760.1 25.960.02 ,0.05
Total cholesterol, mmol/L 5.2860.03 5.4560.01 ,0.05
HDL cholesterol,* mmol/L 1.3060.01 1.2660.003 ,0.05







Alcohol intake, g/wk 141.967.5 153.261.5 z z z
Current smoking status, % 22 18 ,0.05
History of parental CVD, % 25 23 ,0.05
History of CVD, % 7 8 z z z
History of cancer, % 0.7 0.9 z z z
Exercise tolerance, METs† 10.960.07 11.060.01 ,0.05
Uric acid,† mmol/L 0.3460.01 0.3460.01 z z z
GGT,†‡ U/L 23.062.3 24.160.3 z z z
Fasting insulin,§ pmol/L 62.463.0 84.061.8 ,0.05
2-h insulin,§ pmol/L 442.8620.4 570.6613.8 ,0.05
Values are mean6SEM or percentages. METs indicates metabolic equiva-
lents; GGT, g-glutamyltranspeptidase. All variables were adjusted for age, sex,
ethnicity, and study population. To convert values for glucose to millimoles per
liter, divide by 18.01. To convert values for cholesterol to milligrams
per deciliter, multiply by 38.67, and to convert triglycerides to milligrams per
deciliter, multiply by 88.57. To convert values for uric acid to milligrams
per deciliter, multiply by 17.14. To convert values for insulin to micro-U per
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For example, age- and sex-adjusted relative risks (with 95%
CIs) associated with low FPG were 2.1 (1.2 to 3.8) for CVD
mortality and 2.1 (1.4 to 2.8) for all-cause mortality in the
ACLS data. Age- and sex-adjusted relative risks (with 95%
CIs) were 3.4 (1.6 to 7.1) for CVD mortality and 1.7 (1.0 to
3.0) for all-cause mortality in the SAHS data. Age- and
sex-adjusted relative risks (with 95% CIs) associated with
low FPG were 2.3 (1.4 to 3.8) for CVD mortality and 2.2 (1.5
to 2.9) for all-cause mortality in the non-Hispanic whites.
Age- and sex-adjusted relative risks (with 95% CIs) were 3.1
(1.4 to 6.8) for CVD mortality and 1.6 (0.8 to 3.0) for
all-cause mortality in Mexican Americans. The interactions
between study or ethnicity and low FPG on mortality were
not statistically significant. No significant differences for
CVD and all-cause mortality were found between nondiabet-
ics with low FPG and diabetics.
We used Kaplan-Meier curves to test for differences in
mortality rates between participants with low glucose and
those with normal glucose. There were strong associations
between low FPG and CVD and all-cause mortality (Figure
2). Both Wilcoxon and log-rank tests were highly significant
for CVD and all-cause mortality (P,0.0001). Log (2log
[survival function]) estimates were approximately parallel
across the low FPG group and normal glucose group (figure
not shown).
Table 2 shows the association between low FPG and CVD,
cancer, deaths other than cancer or CVD, and all-cause
mortality. Participants with low FPG had substantially higher
CVD, all-cause, and other mortality. The relation between
low FPG and cancer mortality was weak and nonsignificant.
Additional adjustments by multivariate analyses and exclu-
sion of persons with chronic diseases did not alter these
associations. For example, the multivariate-adjusted relative
risks (with 95% CIs) of low FPG for CVD and all-cause
mortality were 2.7 (1.7 to 4.3) and 2.0 (1.5 to 2.6) in all study
subjects, 2.7 (1.5 to 4.7) and 2.0 (1.4 to 2.9) in restricting
Figure 1. CVD and all-cause mortality rates per 1000 person-years, according to FPG levels. Rates in left panel are crude rates; rates
in right panel are adjusted for age, sex, and population. FPG was classified as diabetes ($126 mg/dL), impaired FPG (110 to 125
mg/dL), normal FPG (80 to 89, 90 to 99, and 100 to 109 mg/dL), and low FPG (70 to 79 mg/dL and ,70 mg/dL). To convert values for
glucose to millimoles per liter, divide by 18.01.
Figure 2. Kaplan-Meier survival curves of CVD mortality and all-cause mortality for participants with low (,80 mg/dL) FPG
(n51795, 50 all-cause deaths and 21 CVD deaths) and participants with normal (80 to 109 mg/dL) FPG (n531 863, 571 all-cause
deaths and 206 CVD deaths). The 2 groups were significantly different (P,0.0001). To convert values for glucose to millimoles per
liter, divide by 18.01.
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events after 4 years of follow-up, and 2.7 (1.6 to 4.5) and 2.1
(1.5 to 2.9) in individuals without a history of CVD and
cancer. Among 21 participants who died from CVD in the
low FPG group, 52% of the deaths were due to acute
myocardial infarction, 19% were due to cerebrovascular
hemorrhage, and 10% were due to cardiac arrest. Because of
the small number of cerebrovascular disease deaths in the low
FPG group, no significant association between low FPG and
cerebrovascular disease was detected.
To investigate the possible dose-response relation of low
FPG levels to mortality, we classified those with low FPG
into ,70 mg/dL (,3.89 mmol/L) and 70 to 79 mg/dL
(3.89 to 4.43 mmol/L) groups (Table 3). We found an
inverse gradient (P,0.0001) for CVD and all-cause mor-
tality across FPG categories in analyses adjusted for age,
sex, and study population. Other models included adjust-
ment for age, sex, study population, ethnicity, current
smoking status, high blood pressure, total cholesterol,
body mass index, triglycerides, history of CVD and cancer,
and a family history of CVD. In the fully adjusted model,
those with FPG,70 mg/dL (,3.89 mmol/L) had a
3.3-fold increased risk of CVD mortality, and those with
FPG 70 to 79 mg/dL (3.89 to 4.43 mmol/L) had a 2.0-fold
increased risk compared with patients with FPG 80 to 109
mg/dL (4.44 to 6.05 mmol/L) (test for trendP,0.0001). In
similar analyses, those with FPG,70 mg/dL
(,3.89 mmol/L) had a 2.4-fold increased risk of all-cause
mortality, and those with FPG 70 to 79 mg/dL (3.89 to
4.43 mmol/L) had a 1.8-fold increased risk (test for trend
P,0.0001). Low FPG was associated with low body mass
index (,18.5), low cholesterol level, low diastolic blood
pressure, and current smoking. However, the association
between low FPG and mortality remained the same after
adjustment for or excluding these risk factors. Low FPG
was not associated with ex-drinkers or nondrinkers in the
data.
Discussion
Currently, known risk factors predict'50% to 60% of
clinical CVD,19,20 and it is important to find additional
predictors to improve clinical risk stratification. In the present
study, we found a potential new predictor of CVD with the
observation of an association between low FPG and CVD and
all-cause mortality. This association was strong, independent,
graded across strata of low FPG, and present in 2 separate
cohort studies, the ACLS and the SAHS. To our knowledge,
this is the first report on low FPG associated with CVD and
all-cause mortality. Most of the previous studies categorized
plasma glucose into diabetes or nondiabetes. However, a
recent cohort study in men showed that crude CVD and
all-cause mortality seems to be higher in patients with FPG
,81 mg/dL (4.5 mmol/L), but the authors did not test this
hypothesis.21
The most important adverse effect of hypoglycemia has
been associated with brain damage.22 As an important fuel of
the brain, severely low FPG may induce brain damage and
dysfunction. However, there were only 11 participants with
classic hypoglycemia with FPG,50 mg/dL (,2.78 mmol/L)
in the present study, and the exclusion of these participants
did not alter the results. ECG changes, including ectopic
activity, flattening of the T wave, ST depression, ventricular
tachycardia, and atrial fibrillation, have been reported in
cases of low plasma glucose.6–8 Marques et al23 reported
alteration of ventricular repolarization with lengthening of the
QT interval during insulin-induced experimental low FPG.
Low plasma glucose has been suspected as the cause of high
CVD mortality in diabetic patients with an unstable FPG.24 It
is known that.60% of adults aged 20 to 30 years have
already had atherosclerosis25 and that the prevalence of
atherosclerosis increases as age increases.25,26 We hypothe-
size that long-term exposure to low FPG may serve as a risk
factor of CVD mortality, perhaps through abnormal cardiac
activity and thrombosis, especially in patients with
atherosclerosis.
The relation between moderately low FPG and mortality in
the present study was not confounded by preexisting chronic
disease. After exclusion or adjustment for history of chronic
disease, including CVD and cancer, the magnitude of asso-
TABLE 2. Relative Risk (95% CI) of Low FPG for All-Cause,
CVD, and Cancer Mortality (Group With Normal Glucose
as Reference)
Relative Risk (95% CI)




All-cause 1.9 (1.4–2.6) 2.0 (1.5–2.6)
CVD 2.4 (1.5–3.8) 2.7 (1.7–4.3)
Cancer 1.2 (0.6–2.3) 1.2 (0.6–2.2)
Other† 2.2 (1.3–3.6) 2.2 (1.3–3.5)
*Adjusted for baseline age, sex, population, ethnicity, body mass index,
triglycerides, high blood pressure, total cholesterol, parental CVD, history of
CVD and cancer, current smoking status, and examination years.
†Includes all non-CVD and noncancer deaths.
TABLE 3. Relative Risk (95% CI) of CVD and All-Cause
Mortality, According to FPG Levels
FPG Level
Relative Risk (95% CI)
CVD All-Cause
Adjusted for age, sex, and
population
,70 mg/dL 3.2 (1.3–7.8) 2.3 (1.2–4.4)
70–79 mg/dL 1.9 (1.1–3.2) 1.7 (1.2–2.4)
Normal FPG (80–109 mg/dL) 1.0 1.0
Tests for trend P,0.0001 P,0.0001
Multivariate-adjusted*
,70 mg/dL 3.3 (1.3–8.0) 2.4 (1.3–4.5)
70–79 mg/dL 2.0 (1.2–3.4) 1.8 (1.3–2.5)
Normal FPG (80–109 mg/dL) 1.0 1.0
Tests for trend P,0.0001 P,0.0001
*Adjusted for baseline age, sex, population, ethnicity, body mass index,
triglycerides, high blood pressure, total cholesterol, parental CVD, history of
CVD and cancer, current smoking status, and examination years. To convert
values for glucose to millimoles per liter, divide by 18.01.
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ciation between low FPG and mortality did not change. Some
kinds of occult cancer have been reported to be associated
with symptomatic hypoglycemia1,27; however, the association
between low FPG and cancer mortality in our data was
weak and nonsignificant. We reported that low cardiore-
spiratory fitness is associated with diabetes and impaired
fasting glucose28 and that low fitness was also somewhat
associated with low FPG (Table 1). Some investigators
have reported that hyperinsulinemia is a cause of hypogly-
cemia1; however, compared with persons without low
FPG, study participants with low FPG in the SAHS had
lower fasting insulin and 2-hour postload insulin levels
(Table 1). Uric acid levels also were similar in individuals
with low FPG and in those with normal FPG in our data
(Table 1). Heavy alcohol intake and liver diseases could be
associated with liver dysfunction and hypoglycemia, but
alcohol intake andg-glutamyltranspeptidase were not
higher in individuals with low FPG. When we excluded
patients with a history of jaundice, hepatitis, cirrhosis, or
abnormalg-glutamyltranspeptidase, the results were un-
changed. Low FPG was associated with low body mass
index, low cholesterol, low diastolic blood pressure, and
current smoking. Low body mass index and current smok-
ing may partly explain low FPG; however, the association
between low FPG and mortality remained the same after
adjustment for these potential confounders.
Limitations
The subjects in ACLS were well educated, and.95% were
white.12,13The subjects in the SAHS were randomly recruited
from 3 types of low-, middle-, and high-income neighbor-
hoods, which included a large proportion of Mexican Amer-
icans.4,14,20 Despite the differences in characteristics, results
from both populations for conventional risk factors of CVD
are consistent with each other and with those from other
populations.4,5,12,13,19,20But whether our results also apply to
African Americans and Asian Americans remains to be
determined. There may be some measurement errors in the
assessment of fasting plasma glucose and a small amount of
patients lost to follow-up. However, it is unlikely that
misclassification accounts for the observed association. It is
possible that low FPG was partially due to inflammation,
metabolic abnormalities, or specific diets, but we did not have
data to evaluate these possibilities. Additional human studies
and animal data are needed to investigate these issues.
Conclusions
The association between low FPG and CVD and all-cause
mortality is clinically relevant. Actually, the higher relative
risks of CVD and all-cause mortality in patients with low
FPG were similar to those in patients with diabetes.2,4,5
Clinicians should be aware of this situation and search for
special causes in cases of low FPG. Although association
does not necessarily indicate cause and effect, our data
suggest that low FPG itself may be a cause of high mortality
risk. If our results are confirmed, low FPG could be a
modifiable risk factor in nondiabetics. The optimal goals
associated with FPG in diabetics taking insulin or oral
antidiabetic agents might be to achieve an FPG level not,80
mg/dL. Further study is needed to explore the cause of low
FPG and the association between low plasma glucose and
CVD and all-cause mortality.
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11. Boyle CA, Decouflé P. National sources of vital status information:
extent of coverage and possible selectivity in reporting.Am J Epidemiol.
1990;131:160–168.
12. Blair SN, Kohl HW III, Paffenbarger RSJ, Clark DG, Cooper KH,
Gibbons LW. Physical fitness and all-cause mortality: a prospective study
of healthy men and women.JAMA. 1989;262:2395–2401.
13. Blair SN, Kampert JB, Kohl HW, Barlow CE, Macera CA, Paffenbarger
RSJ, Gibbons LW. Influences of cardiorespiratory fitness and other pre-
cursors on cardiovascular disease and all-cause mortality in men and
women.JAMA. 1996;276:205–210.
14. Stern MP, Rosenthal M, Haffner SM, Hazuda HP, Franco LJ. Sex dif-
ference in the effects of sociocultural status on diabetes and cardiovas-
cular risk factors in Mexican Americans: The San Antonio Heart Study.
Am J Epidemiol. 1984;120:834–851.
15. The Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus. Report of the Expert Committee on the Diagnosis and Classi-
fication of Diabetes Mellitus.Diabetes Care. 1997;20:1183–1197.
16. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B,
Hennekens CH. Test of the National Death Index.Am J Epidemiol.
1984;119:837–839.
17. SAS Institute Inc.SAS/STAT User’s Guide, Version 6. Cary, NC: SAS
Institute Inc; 1989.
18. Greenland S. Modeling and variable selection in epidemiologic analysis.
Am J Public Health. 1989;79:340–349.
Wei et al Low Fasting Plasma Glucose and Mortality 2051
 at University of South Carolina--Columbia on June 11, 2013http://circ.ahajournals.org/Downloaded from 
19. Heller RF, Chinn S, Pedoe HDT, Rose G. How well can we predict
coronary heart disease? Findings in the United Kingdom Heart Disease
Prevention Project.BMJ. 1984;288:1409–1411.
20. Wei M, Mitchell BD, Haffner SM, Stern MP. Effects of cigarette
smoking, diabetes, high cholesterol, and hypertension on all-cause mor-
tality and cardiovascular disease mortality in Mexican Americans: The
San Antonio Heart Study.Am J Epidemiol. 1996;144:1058–1065.
21. Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J,
Erikssen J, Thaulow E. Fasting blood glucose: an underestimated risk
factor for cardiovascular death.Diabetes Care. 1999;22:45–49.
22. Malouf R, Brust JC. Hypoglycemia: causes, neurological manifestations,
and outcome.Ann Neurol. 1985;17:421–430.
23. Marques JLB, George E, Peacey SR, Harris ND, Macdonald IA,
Cochrane T, Heller SR. Altered ventricular repolarization during hypo-
glycaemia in patients with diabetes.Diabet Med. 1997;14:648–654.
24. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R.
Long-term instability of fasting plasma glucose, a novel predictor of
cardiovascular mortality in elderly patients with non-insulin-dependent
diabetes mellitus: The Verona Diabetes Study.Circulation. 1997;96:
1750–1754.
25. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE,
Wattigney WA. Association between multiple cardiovascular risk factors
and atherosclerosis in children and young adults: The Bogalusa Heart
Study.N Engl J Med. 1998;338:1650–1656.
26. Tejada C, Strong JP, Montenegro MR, Restrepo C, Solberg LA. Distri-
bution of coronary and aortic atherosclerosis by geographic location, race,
and sex.Lab Invest. 1968;18:509–526.
27. Trivedi N, Mithal A, Sharma AK, Mishra SK, Pandey R, Trivedi B,
Daughaday WH. Non-islet cell tumour induced hypoglycaemia with acro-
megaloid facial and acral swelling.Clin Endocrinol (Oxf). 1995;42:
433–435.
28. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD, Blair SN. The
association between cardiorespiratory fitness and impaired fasting
glucose and type 2 diabetes mellitus in men.A n Intern Med. 1999;130:
89–96.
2052 Circulation May 2, 2000
 at University of South Carolina--Columbia on June 11, 2013http://circ.ahajournals.org/Downloaded from 
